Dr. Stansfield has worked in the commercial sector of some of the largest animal health companies for more than 40 years.  He has experience in business startups as well as multi-platform large commercial operations in the Animal Health Sector. His stellar career comprises of leading cutting edge medical education for the veterinary profession, working with specialists in academia and the private sector and he has led some of the best assembled Key Opinion Leader Advisory Boards in the industry.  Some of his largest accomplishments include conceptualizing and leading the formation of the Companion Animal Parasite Council (CAPC), a Founding Board Member of Specialist Outreach Awareness Program (VetSOAP) and an active board member of CATalyst, a feline health care advocacy group. He has also been a key member of numerous launch teams for some of the industry’s largest and game-changing brands like Apoquel® (oclacitinib), Atopica® (cyclosporine), Capstar® (nitenpyram), Convenia® (cefovecin), Deramaxx® (deracoxib), Fasinex® (triclabendazole), Interceptor® (milbemycin oxime), Palladia® (toceranib phosphate), Percorten®-V (DOCP), Program® (lufenuron) and Sentinel® (milbemycin oxime/lufenuron).  He has given more than 300 lectures in the areas of dermatology, endocrinology, oncology, pain, parasitology, sedation as well as broad based topics such as the “referral hospital relationship” and “significant ways for the betterment of the animal, the veterinarian and the pet owner”.

Dr. Stansfield currently consults with both large and small companies in the areas of new product launches, key opinion leader (KOL) management, specialty hospital management and crisis management.   Prior to going out on his own, he had numerous leadership roles with large animal health companies for more than 30 years.  Most recently at Zoetis (formerly Pfizer Animal Health), he was the Director of Specialty Hospital Services and the Director of Veterinary Strategic Services whereby he built relationships with key influencers in the areas of sedation, dermatology, pain and parasitology.  He was also a Specialty Hospital Liaison developing and implementing programs with KOLs and Colleges of Veterinary Medicine.

 

Dr. Stansfield began his career in industry as the Head of Development and Technical Services leading the product development team and technical support to sales and marketing in Cambridge, England for what was then Ciba-Geigy Animal Health.  When Novartis Animal Health was formed, he relocated to the US and single-handedly built and led the entire professional services and pharmacovigilance organization consisting of 40 veterinary professionals and para professionals as the Director of Professional Services.  His last role with Novartis Animal Health was as the Director of Professional Relations focusing on KOL relationships and referral centers.

He also has substantial equine experience; he has worked at an equine practice and owned and operated an equine facility for 30 years.  A fun and interesting side-note to his time in equine medicine was that that one of his patients was a Polo Pony, owned by the famous, Ginger Baker,  (the drummer for the band, Cream).  

 

He currently volunteers as part-time Veterinary Medical Director of the Randolph County SPCA and is an interpretive guide at the North Carolina Zoo.

Dr. David Stansfield has earned extensive Business Continuing Education Credits in the areas of middle and senior management training, speaker training, media training, team building and leadership, is a Member of the Royal College of Veterinary Surgeons (MRCVS) and holds a Bachelors of Veterinary Science (BVSc) from the Liverpool John Moores University School of Veterinary Medicine.

For more information, visit https://www.linkedin.com/in/david-stansfield-9733304/

 

Publications: 

Treatment of Baylisascaris procyonis infections in dogs with milbemycin oxime. Bowman D.D., Ulrich M.A., Gregory D.E., Neumann N.R, Legg W., and Stansfield, D. Vet Parasitology. Vol 129 p285 – 290. May 2005

Efficacy and Longevity of Nitenpyram against Adult Cat Fleas (Siphonaptera:Pulicidae) Rust M.K., Waggoner M.W., Hinkle N.C., Stansfield D., Barnett S., J of Med. Ent. Vol 40, (5) p 678 – 671, 2003

Efficacy of Moxidectin 6-month injectable and Milbemycin/Lufenuron tablets against naturally acquired Toxocara canis infections in dogs. Bowman D.D., Leg, W. and Stansfield D.G. Veterinary Therapeutics 3(3)281-285 2002

Efficacy of Moxidectin 6-month injectable and Milbemycin/Lufenuron tablets against naturally acquired Trichuris vulpis infections in dogs. Bowman D.D., Leg, W. and Stansfield D.G. Veterinary Therapeutics 3(3)286 – 289 2002

Response of Dogs treated with Ivermectin or Milbemycin starting at various intervals after Dirofilaria immitis infection. Rawlings C.A., Bowman D.D., Howerth E.W., Stansfield D.G., Legg W., Luempert III L.G. Vet Therapeutics  Summer;2(3):193 - 207, 2001.

Efficacy of Milbemycin oxime against 4th stage larvae of Toxocara canis. Hotz R.P.., Sager H., Cody R., Buescher G., and Stansfield D.G. Proceedings of the American Association of Veterinary Parasitologists, July 14th – 17th 2001

Disease response to Trickle Kill when Ivermectin or Milbemycin Oxime is started during Dirofilaria immitis infection in dogs   Rawlings C., Bowman D.D., Howerth E.W.,  Stansfield D.G. and Legg W. Recent Advances in Heartworm Disease 179 – 187, 2001.

Effects of Avermectins on Microfilariae in dogs with existing and developing heartworm infections Bowman D.D., Neumann N.R., Rawlings C., Stansfield D.G. and Legg W. Recent Advances in Heartworm Disease. 173  - 178 2001.

The efficacy of Milbemycin Oxime/ Lufenuron and Selamectin treating adult intestinal nematodes (Ancylostoma caninum, Toxocara canis and Trichuris vulpis) Bowman D.D., Stansfield D.G. and Thoren J.H. Proceedings of the American Association of Veterinary Parasitologists, July 22nd – 25th 2000

Efficacy of a combined formulation of Milbemycin oxime and Lufenuron in controlling flea infestations. Pengo G., Sica P., Steiger R., Stansfield D.G. Proceedings of the American Association of Veterinary Parasitologists, July 19th – 22nd 1997.

Effects of Nitroscanate on adult Taenia pisiformis in dogs with experimentally induced infections. Bowman, D.D, Lin, D.S., Johnson, R.C., Lynn, R.C., Hepler, D.I. and Stansfield, D.G. Am.J.Vet.Res.1991 52 (9) 1542- 1544

Safety and Efficacy of Milbemycin Oxime for parasite control. Stansfield, D.G. and Hepler, D.I. Canine Practice

David Stansfield, BVSc, MRCVS

Veterinary Consultant

5820 N. Church Street, Suite D#213, Greensboro, NC 27455 | 336.209.4941
  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon

By using this site you agree that we can place cookies on your device. See our Privacy Policy and Cookie Policy for details.

© 2019 Scullion Strategy Group, LLC. All Rights Reserved.